Novel Angiogenic Signaling Pathways and Vascular Targets

Annual Review of Pharmacology and Toxicology

Volumn 44, Issue , 2004, Pages 219-238

  Bicknell, Roy ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; EPHRIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR DERIVATIVE; NOTCH RECEPTOR; ROUNDABOUT RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; EXTRACELLULAR SPACE; GENE EXPRESSION; GENE INDUCTION; HUMAN; HYPOXIA; INTRACELLULAR SPACE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD VESSELS; CANCER VACCINES; CELL HYPOXIA; HUMANS; LIGANDS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ERINACEIDAE;

EID: 1342287074     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.44.101802.121650     Document Type: Review

References (109)

1. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-48
2. Bikfalvi A, Bicknell R. 2002. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol. Sci. 23:576-82
3. Harris AL. 2002. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38-47
4. 2-regulated prolyl hydroxylation. Science 292:468-72
5. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54
6. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. 2001. HIF-alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464-68
7. Leek RD, Talks KL, Pezzella F, Turley H, Campo L, et al. 2002. Relation of hypoxia-inducible factor-2alpha (HIF-2alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res. 62:1326-29
8. Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, et al. 2003. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. J. Biol. Chem. 278:1802-6
9. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, et al. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111:709-20
10. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. 2001. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21:3995-4004
11. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. 2002. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J. Biol. Chem. 277:40112-17
12. Berra E, Milanini J, Richard DE, LeGall M, Vinals F, et al. 2000. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 60:1171-78
13. Pilch H, Schlenger K, Steiner E, Brockerhoff P, Knapstein P, Vaupel P. 2001. Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts. Int. J. Gynecol. Cancer 11:137-42
14. Ozawa K, Kondo T, Hori O, Kitao Y, Stem DM, et al. 2001. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J. Clin. Invest. 108:41-50
15. Shimo T, Kubota S, Kondo S, Nakanishi T, Sasaki A, et al. 2001. Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line. Cancer Lett. 174:57-64
16. Ambrosini G, Nath AK, Sierra-Honigmann MR, Flores-Riveros J. 2002. Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J. Biol. Chem. 277:34601-9
17. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. 2002. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 46:2587-97
18. Bacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, et al. 2003. Upregulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am. J. Pathol. 162:11-17
19. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, et al. 2001. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res. 61:2696-703
20. Murray B, Wilson DJ. 2001. A study of metabolites as intermediate effectors in angiogenesis. Angiogenesis 4:71-77
21. Guppy M. 2002. The hypoxic core: a possible answer to the cancer paradox. Biochem. Biophys. Res. Commun. 299:676-80
22. Brahimi-Horn C, Berra E, Pouyssegur J. 2001. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol. 11:S32-36
23. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. 2003. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol. Cancer Ther. 2:235-43
24. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. 2001. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8:638-45
25. Willam C, Masson N, Tian YM, Mahmood SA, Wilson MI, et al. 2002. Peptide blockade of HIF-alpha degradation modulates cellular metabolism and angiogenesis. Proc. Natl. Acad. Sci. USA 99:10423-28
26. Clauss M. 2000. Molecular biology of the VEGF and the VEGF receptor family. Semin. Thromb. Hemost. 26:561-69
27. Li XR, Eriksson U. 2001. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell Biol. 33:421-26
28. Matsumoto T, Claesson-Welsh L. 2001. VEGF receptor signal transduction. Sci. STKE 2001:RE21
29. Poltorak Z, Cohen T, Neufeld G. 2000. The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. Herz 25:126-29
30. Robinson CJ, Stringer SE. 2001. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114:853-65
31. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, et al. 2001. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28:131-38
32. Witmer AN, van Blijswijk BC, Dai J, Hofman P, Partanen TA, et al. 2001. VEGFR-3 in adult angiogenesis. J. Pathol. 195:490-97
33. Walter JW, North PE, Waner M, Mizeracki A, Blei F, et al. 2002. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 33:295-303
34. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. 2003. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63:812-16
35. Li Y, Wang MN, Li H, King KD, Bassi R, et al. 2002. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195:1575-84
36. Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. 2002. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl. Acad. Sci. USA 99:7009-14
37. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, et al. 2001. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412:877-84
38. Lin DC, Bullock CM, Ehlert FJ, Chen JL, Tian H, Zhou QY. 2002. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J. Biol. Chem. 277:19276-80
39. Masuda Y, Takatsu Y, Terao Y, Kumano S, Ishibashi Y, et al. 2002. Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors. Biochem. Biophys. Res. Commun. 293:396-402
40. LeCouter J, Lin R, Tejada M, Frantz G, Peale F, et al. 2003. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: localization of Bv8 receptors to endothelial cells. Proc. Natl. Acad. Sci. USA 100:2685-90
41. Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, et al. 2003. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin. Cancer Res. 9:264-72
42. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:575-83
43. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, et al. 2002. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8:841-49
44. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, et al. 2002. Revascularization of ischemic tissues by P1GF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8:831-40
45. Pipp F, Heil M, Issbrucker K, Ziegelhoeffer T, Martin S, et al. 2003. VEGFR-1-selective VEGF homologue P1GF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ. Res. 92:378-85
46. Adini A, Kornaga T, Firoozbakht F, Benjamin LE. 2002. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res. 62:2749-52
47. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, et al. 2002. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive P1GF-1/VEGF heterodimers. Cancer Cell 1:99-108
48. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. 2002. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 62:7042-49
49. Klagsbrun M, Takashima S, Mamluk R. 2002. The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 515:33-48
50. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. 2002. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 12:13-19
51. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. 2002. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell Biochem. 85:357-68
52. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, et al. 2000. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc. Natl. Acad. Sci. USA 97:2573-78
53. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. 2000. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J. 14:2532-39
54. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, et al. 2001. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61:5736-40
55. Bachelder RE, Wendt MA, Mercurio AM. 2002. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 62:7203-6
56. Fuh G, Garcia KC, de Vos AM. 2000. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J. Biol. Chem. 275:26690-95
57. Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, et al. 2002. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc. Natl. Acad. Sci. USA 99:3657-62
58. Neufeld G, Kessler O, Herzog Y. 2002. The interaction of neuropilin-1 and neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv. Exp. Med. Biol. 515:81-90
59. Shima DT, Mailhos C. 2000. Vascular developmental biology: getting nervous. Curr. Opin. Genet Dev. 10:536-42
60. Bates D, Taylor GI, Minichiello J, Farlie P, Cichowitz A, et al. 2003. Neurovascular congruence results from a shared patterning mechanism that utilizes semaphorin3A and neuropilin-1. Dev. Biol. 255:77-98
61. Baron M, Aslam H, Flasza M, Fostier M, Higgs JE, et al. 2002. Multiple levels of Notch signal regulation (review). Mol. Membr. Biol. 19:27-38
62. Kalaria RN, Low WC, Oakley AE, Slade JY, Ince PG, et al. 2002. CADASIL and genetics of cerebral ischaemia. J. Neural Transm. 63(Suppl.):75-90
63. Iso T, Hamamori Y, Kedes L. 2003. Notch signaling in vascular development. Arterioscler. Thromb. Vasc. Biol. 13:13
64. Shimizu K, Chiba S, Saito T, Kumano K, Takahashi T, Hirai H. 2001. Manic fringe and lunatic fringe modify different sites of the Notch2 extracellular region, resulting in different signaling modulation. J. Biol. Chem. 276:25753-58
65. Lai EC. 2002. Protein degradation: four E3s for the Notch pathway. Curr. Biol. 12:R74-78
66. Uyttendaele H, Ho J, Rossant J, Kitajewski J. 2001. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc. Natl. Acad. Sci. USA 98:5643-48
67. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. 2001. Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69:135-44
68. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, et al. 2000. D114, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 14:1313-18
69. Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, Weinmaster G. 2001. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech. Dev. 108:161-64
70. Lawson ND, Scheer N, Pham VN, Kim CH, Chitnis AB, et al. 2001. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 128:3675-83
71. Iso T, Sartorelli V, Poizat C, Iezzi S, Wu HY, et al. 2001. HERP, a novel heterodimer partner of HES/E(sp1) in Notch signaling. Mol. Cell Biol. 21:6080-89
72. Zimrin AB, Pepper MS, McMahon GA, Nguyen F, Montesano R, Maciag T. 1996. An antisense oligonucleotide to the Notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro. J. Biol. Chem. 271:32499-502
73. Leong KG, Hu X, Li L, Noseda M, Larrivee B, et al. 2002. Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol. Cell Biol. 22:2830-41
74. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, et al. 2003. Regulation of Notch1 and D114 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol. Cell Biol. 23:14-25
75. Taylor KL, Henderson AM, Hughes CC. 2002. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc. Res. 64:372-83
76. Ascano JM, Beverly LJ, Capobianco AJ. 2003. The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J. Biol. Chem. 278:8771-79
77. Itoh M, Kim CH, Palardy G, Oda T, Jiang YJ, et al. 2003. Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by delta. Dev. Cell 4:67-82
78. Adams RH. 2002. Vascular patterning by Eph receptor tyrosine kinases and ephrins. Cell Dev. Biol. 13:55-60
79. Cheng N, Brantley DM, Chen J. 2002. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 13:75-85
80. Adams RH, Diella F, Hennig S, Helmbacher F, Deutsch U, Klein R. 2001. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 104:57-69
81. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. 1995. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 268:567-69
82. Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, et al. 1998. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 12:667-78
83. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. 2000. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19:6043-52
84. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, et al. 2002. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21:7011-26
85. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, et al. 2002. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 1:2-11
86. a. Martiny-Baron G, Wood J, Esser N, Weindel K, Marme D. 2001. EphB receptors and Ephrin ligands are involved in tumour growth and angiogenesis in A375 melanoma xenografts. Am. Assoc. Cancer Res. Annu. Meet. Abstr. 4154
87. Pola R, Ling LE, Silver M, Corbley MJ, Kearney M, et al. 2001. The morphogen sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 7:706-11
88. Lawson ND, Vogel AM, Weinstein BM. 2002. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev. Cell 3:127-36
89. Mailleux AA, Tefft D, Ndiaye D, Itoh N, Thiery JP, et al. 2001. Evidence that SPROUTY2 functions as an inhibitor of mouse embryonic lung growth and morphogenesis. Mech. Dev. 102:81-94
90. Lee SH, Schloss DJ, Jarvis L, Krasnow MA, Swain JL. 2001. Inhibition of angiogenesis by a mouse sprouty protein. J. Biol. Chem. 276:4128-33
91. Hanafusa H, Torii S, Yasunaga T, Nishida E. 2002. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 4:850-58
92. Seeger M, Tear G, Ferres-Marco D, Goodman CS. 1993. Mutations affecting growth cone guidance in Drosophila: genes necessary for guidance toward or away from the midline. Neuron 10:409-26
93. Brose K, Bland KS, Wang KH, Arnott D, Henzel W, et al. 1999. Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 96:795-806
94. Kidd T, Brose K, Mitchell KJ, Fetter RD, Tessier-Lavigne M, et al. 1998. Round-about controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell 92:205-15
95. Huminiecki L, Bicknell R. 2000. In silico cloning of novel endothelial-specific genes. Genome Res. 10:1796-806
96. Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R. 2002. Magic round-about is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79:547-52
97. Bashaw GJ, Kidd T, Murray D, Pawson T, Goodman CS. 2000. Repulsive axon guidance: abelson and enabled play opposing roles downstream of the roundabout receptor. Cell 101:703-15
98. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, et al. 2000. Genes expressed in human tumor endothelium. Science 289:1197-202
99. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. 2001. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 61:6649-55
100. Helmlinger G, Yuan F, Dellian M, Jain RK. 1997. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3:177-82
101. Kahn J, Mehraban F, Ingle G, Xin XH, Bryant JE, et al. 2000. Gene expression profiling in an in vitro model of angiogenesis. Am. J. Pathol. 156:1887-900
102. Roland I, Minet E, Ernest I, Pascal T, Michel G, et al. 2000. Identification of hypoxia-responsive messengers expressed in human microvascular endothelial cells using differential display RT-PCR. Eur. J. Biochem. 267:3567-74
103. Zhang H, Gorn M, Smith K, Graham A, Lau K, Bicknell R. 1999. Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis 3:211-19
104. McIntosh DP, Tan XY, Oh P, Schnitzer JE. 2002. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. USA 99:1996-2001
105. Pasqualini R, Arap W, McDonald DM. 2002. Probing the structural and molecular diversity of tumor vasculature. Trends Mol. Med. 8:563-71
106. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8:751-55
107. Ruoslahti E. 2002. Specialization of tumour vasculature. Nat. Rev. Cancer 2:83-90
108. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, et al. 1999. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401:670-77
109. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, et al. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-201